Fig. 2

Icaritin induces durable partial response and immune biomarkers. a. Time course images (MRI and RECIST1.1) of a PR patient demonstrate tumour shrinkage after 8, 16 and 32 weeks of icaritin treatment compared to the baseline image. The CT images show that the retroperitoneal multiple lymph node metastases (not liver tumour lesion; multiple lesion sites are indicated by the arrows in red) were significantly reduced during the time course of icaritin treatment. The red arrows indicate lesions with diameter > 1.5 cm at baseline and week 8 of treatment. After 16 weeks of treatment, target lesions were evaluated as complete response (CR) (with maximum measurable diameter < 0.5 cm) according to RECIST1.1. b. Dynamic changes of AFP biomarkers and cytokine panel (IL-6, IL-8 IL-10, ΤΝF-α, and IFN-γ) in the time course of icaritin treatment. (Note: The time course tumour CT 3D-tomography images may not from identical sections, but they are valid for comparison of the dynamic changes and drug efficacy. a) By selecting the section with the maximum diameter of lesion using the RECIST1.1 global standard, the section location reference was according to the great vessels of the retroperitoneum, especially the large vessels of the retroperitoneum. b) Tumour shrinkage asymmetrically. c) CT section of images of organs may vary from time to time due to breath and other uncontrolled factors of patient)